

CURRICULUM VITAE

Reena S. Cecchini, MS, PhD

BUSINESS ADDRESS: One Sterling Plaza Phone: 412-624-6956
201 N. Craig St., Suite 350 Fax: 412-383-1387
Pittsburgh, PA 15213 E-mail: rls18@pitt.edu

EDUCATION AND TRAINING

Graduate

1/2007 – 4/2012	University of Pittsburgh Pittsburgh, PA	PhD, 2012	Epidemiology
8/2002 – 4/2004	University of Pittsburgh Pittsburgh, PA	MS, 2004	Biostatistics

Undergraduate

8/1998 – 5/2002	Allegheny College Meadville, PA	BS, 2002	Mathematics
-----------------	------------------------------------	----------	-------------

APPOINTMENTS AND POSITIONS

Academic

7/2013 – Present	Research Assistant Professor	Biostatistics, Graduate School of Public Health University of Pittsburgh, Pittsburgh, PA
8/2012 – 6/2013	Visiting Research Assistant Professor	Biostatistics, Graduate School of Public Health University of Pittsburgh, Pittsburgh, PA

Non-Academic

3/2014 – Present	Senior Biostatistician	NRG Oncology, Statistics and Data Management Center (formerly NSABP) Pittsburgh, PA
8/2012 – 2/2014	Protocol Statistician	National Surgical Adjuvant Breast and Bowel Project (NSABP), Biostatistical Center Pittsburgh, PA
5/2004 – 7/2012	Research Statistician	National Surgical Adjuvant Breast and Bowel Project (NSABP), Biostatistical Center Pittsburgh, PA

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

2012 – Present American Statistical Association
2012 – Present Pennsylvania Public Health Association

HONORS AND AWARDS

2001-2002 Pi Mu Epsilon (The National Honorary Mathematics Society), Allegheny College
2001-2002 Psi Chi (The National Honor Society in Psychology), Allegheny College
1999-2002 Alden Scholar, Allegheny College

RESEARCH

Current Research Support

Funding Agency: NRG Oncology Foundation INC. (Primary Funding Agency NCI)
Grant Number: 5UG1CA189867
Title of Grant: NRG Oncology NCORP Research Base-SDMC
Principal Investigators: Deb Bruner, Joan Walker, Donald Lawrence Wickerham
Principal Investigator: Joseph P. Costantino (PI of SDMC)
Cecchini Role on Grant: Statistician
Years Inclusive: 8/2014 - 7/2019
Percent Effort: 70.0 %
Total Direct Costs: \$13,363,077 (for all 3 sites, Pitt, Buffalo, Philadelphia)
Total Direct Costs U of P: \$5,141,357

Funding Agency: National Cancer Institute
Grant Number: 2U10CA180822
Title of Grant: NRG Oncology Statistical and Data Management Center
Principal Investigator: Jim Dignam
Cecchini Role on Grant: Statistician
Years Inclusive: 3/2019 - 2/2025
Percent Effort: 30.0 %
Total Direct Costs: \$60,799,128

Pending Research Support

Funding Agency: NCI via subcontract with the University of Chicago
Grant Number: 2UG1CA189867
Title of Grant: NRG Oncology SDMC - NCORP Research Base
Principal Investigators: Deb Bruner and Joan Walker
Principal Investigator: Jim Dignam (PI of SDMC)
Cecchini Role on Grant: Statistician
Years Inclusive: 8/2019 - 7/2025
Percent Effort: 70.0 %
Total Direct Costs: \$5,505,703

Past Research Support

Funding Agency: NSABP Foundation INC.
Grant Number: NSABP B-46-I
Title of Grant: Phase III Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator: Joseph P. Costantino
Cecchini Role on Grant: Statistician
Years Inclusive: 5/2009 - 12/2021
Percent Effort: 20.0 %
Total Direct Costs: \$4,572,935

Funding Agency: National Cancer Institute
Grant Number: 5 U10 CA069974
Title of Grant: CCOP Biostatistical Center
Principal Investigator: Joseph P. Costantino
Cecchini Role on Grant: Protocol Statistician
Years Inclusive: 6/2012 - 7/2014
Percent Effort: 70.0 %
Total Direct Costs: \$5,352,751

Funding Agency: National Cancer Institute
Grant Number: 5 U10 CA069651
Title of Grant: Biostatistical Center for the NSABP
Principal Investigator: Joseph P. Costantino
Cecchini Role on Grant: Protocol Statistician
Years Inclusive: 2/2006 - 2/2014
Percent Effort: 10.0 %
Total Direct Costs: \$2,534,758

PUBLICATIONS

Refereed Articles

1. Cook ED, Yeager KA, **Cecchini RS**, Boparai J, Brown CL, Duncan M, Cronin WM, Paskett ED. Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. *Contemporary Clinical Trials Communications* 2018 June; 10: 100-104. doi:10.1016/j.conctc.2018.03.003 Epub 2018 Mar 9.
2. Ganz PA, Romond EH, **Cecchini RS**, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: A randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with ac followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. *J Clin Oncol.* 2017 Dec 10;35(35):3942-3948. doi: 10.1200/JCO.2017.74.1165. Epub 2017 Oct 26. PMID: 29072977
3. **Cecchini RS**, Swain SW, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34 and B-38. *Cancer Epidemiol Biomarker Prev.* 2016 Jan 25; 25 (1):51-9. PMID: 26545405. doi: 10.1158/1055-9965.EPI-15-0334-T.
4. Margolese L, **Cecchini RS**, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. *Lancet.* 2015 Dec 10; online. PMID: 26686957. doi: [http://dx.doi.org/10.1016/S0140-6736\(15\)01168-x](http://dx.doi.org/10.1016/S0140-6736(15)01168-x).
5. Ganz PA, **Cecchini RS**, Julian TB, Margolese R, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. *Lancet.* 2015 Dec 10; online. PMID: 26686960. doi: [http://dx.doi.org/10.1016/S0140-6736\(15\)01169-1](http://dx.doi.org/10.1016/S0140-6736(15)01169-1).
6. Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, **Cecchini RS**, Kopec JA, Wolmark N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. *Cancer.* 2012 Nov 15; 118 (22):5614-22. PMID: 22569841. doi: 10.1002/cncr.27593.

7. **Cecchini RS**, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). *Cancer prevention research (Philadelphia, Pa.)*. 2012 Nov; 5 (11):1321-9. PMID: 23060039.
8. Amir E, **Cecchini RS**, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. *Breast cancer research and treatment*. 2012 Jun; 133 (3):1077-88. PMCID: PMC3396331. PMID: 22415479.
9. **Cecchini RS**, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, Weissfeld JL, Wolmark N. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. *Cancer prevention research (Philadelphia, Pa.)*. 2012 Apr; 5 (4):583-92. PMID: 22318751.
10. Runowicz CD, Costantino JP, Wickerham DL, **Cecchini RS**, Cronin WM, Ford LG, Vogel VG, Wolmark N. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). *American journal of obstetrics and gynecology*. 2011 Dec; 205 (6):535.e1-5. PMID: 21872200.
11. Sucato GS, Land SR, Murray PJ, **Cecchini R**, Gold MA. Adolescents' experiences using the contraceptive patch versus pills. *Journal of pediatric and adolescent gynecology*. 2011 Aug; 24 (4):197-203. PMID: 21454110.
12. Ganz PA, Land SR, Geyer CE Jr, **Cecchini RS**, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011 Mar 20; 29 (9):1110-6. PMCID: PMC3083866. PMID: 21300930.
13. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, **Cecchini RS**, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. *Cancer prevention research (Philadelphia, Pa.)*. 2010 Jun; 3 (6):696-706. PMCID: PMC2935331. PMID: 20404000.
14. Swain SM, Land SR, Ritter MW, Costantino JP, **Cecchini RS**, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. *Breast cancer research and treatment*. 2009 Jan; 113 (2):315-20. PMID: 18302020.
15. Wickerham DL, Costantino JP, Vogel VG, Cronin WM, **Cecchini RS**, Ford LG, Wolmark N. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent results in cancer research. *Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*. 2009; 181:113-9. PMID: 19213563.

16. Land SR, Kopec JA, **Cecchini RS**, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007 Jun 1; 25 (16):2205-11. PMID: 17470850.
17. Deutsch M, Land SR, Begovic M, **Cecchini R**, Wolmark N. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. *American journal of clinical oncology*. 2007 Jun; 30 (3):294-6. PMID: 17551308.
18. Kopec JA, Yothers G, Ganz PA, Land SR, **Cecchini RS**, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. *Journal of Clinical Oncology : Official Journal of The American Society of Clinical Oncology*. 2007 Feb 1; 25 (4):424-30. PMID: 17264338. doi: 10.1200/JCO.2005.05.2597.
19. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, **Cecchini RS**, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA : the journal of the American Medical Association*. 2006 Jun 21; 295 (23):2727-41. PMID: 16754727.
20. Kopec JA, Land SR, **Cecchini RS**, Ganz PA, Cella D, Costantino JP, Wieand HS, Smith RE, Kuebler JP, Wolmark N. Validation of a Self-Reported Neurotoxicity Scale in Patients with Operable Colon Cancer Receiving Oxaliplatin. *Journal of Supportive Oncology*. 2006; 4 (8):W1-W8.
21. Fisher B, Costantino JP, Wickerham DL, **Cecchini RS**, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *Journal of the National Cancer Institute*. 2005 Nov 16; 97 (22):1652-62. PMID: 16288118.

Published Abstracts and Presentations

1. Ganz PA, **Cecchini RS**, White JR, Vicini F, Julian TB, Arthur DW, Rabinovitch R, Kuske RR, Parda DS, Scheier M, Winter KA, Paik S, Kuerer M, Vallow L, Pierce LJ Mamounas EP, Costantino JP, McCormick B, Curran, Jr. WJ, Wolmark N. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. [abstract]. *Journal of Clinical Oncology*. 2019; 37. *Presented at the 2019 ASCO Annual Meeting, Jun 3, Chicago, IL.*

2. Pogue-Geile KL, Wang Y, Feng H, Lipchik C, Kim RS, **Cecchini RS**, Jacobs SA, Srinivasan A, Costantino JP, Mamounas EP, Geyer CE, Rastogi P, Lucas PC, Paik S, Osborne KC, Wolmark N, Rimawi M. Association of molecular signatures, mutations and sTILs with pCR in breast cancer patients in NRG Oncology/NSABP B-52. [abstract]. In: Proceedings of the 97th annual meeting of the American Association for Cancer Research; 2019 Mar 29-Apr 3; Atlanta GA. Philadelphia (PA): AACR; 2019. Abstract nr 4064.
3. Vicini FA, **Cecchini RS**, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Peterson IA, Hudes RS, Curran WJ, Wolmark N. Primary Results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. [abstract]. Cancer Research. 2019; 79. Presented at the 2018 SABCS. Dec 4-8, San Antonio, TX.
4. De Azambuja E, Ponde NF, Procter MJ, Rastogi P, **Cecchini RS**, Ballman KV, Moreno-Aspitia A, Zardavas D, Roca L, Gelber RD, Piccart M, Suter TM. Meta-analysis of the cardiac events in the adjuvant trastuzumab trials. [abstract]. Journal of Clinical Oncology. 2018; 36(15S). Presented at the 2018 ASCO Annual Meeting, Jun 4, Chicago, IL.
- 5.. Fehrenbacher L, **Cecchini RS**, Geyer CE, Rastogi P, Costantino JP, Atkins JN, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Borges V, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) -> weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+or 2+with negative FISH (HER2-Low IBC). [abstract]. Cancer Research. 2018; 78. Presented at the 2017 SABCS, Dec 5-9, San Antonio, TX.
- 6.. Rimawi MF, **Cecchini RS**, Rastogi P, Geyer CE, Fehrenbacher L, Stella PJ, Dayao Z, Rabinovitch R, Dyar SH, Flynn PJ, Baez-Diaz L, Paik S, Swain SM, Mamounas EP, Osborne CK, Wolmark N. A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52. [abstract]. Cancer Research. 2017; 77. Presented at the 2016 SABCS, Dec 6-10, San Antonio, TX.
7. Ganz PA, **Cecchini RS**, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori SS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy + radiotherapy [abstract]. Cancer Research. 2016; 76(4S). Presented at the 2015 SABCS, Dec 8-12, San Antonio, TX.

- 8.. Margolese R, **Cecchini RS**, Julian TB, Ganz PA, Costantino JP, Allred C, Vallow LA, Albain KS, Whitworth P, Cianfrocca ME, Gross HM, Brufsky AM, Soori G, Atkins JN, Fehrenbacher L, Sturtz K, Biggs DD, Seay TE, Mamounas EP, Wolmark N. Primary results of NRG/NSABPB-35: A clinical trial comparing anastrozole with tamoxifen in postmenopausal patients with ductal carcinoma in situ undergoing lumpectomy with radiotherapy. [abstract]. *Journal of Clinical Oncology*. 2015; 33(15S). *Presented at the 2015 ASCO Annual Meeting, Jun 1, Chicago, IL.*
9. Wickerham L, **Cecchini RS**, Vogel VG, Costantino JP, Cronin WM, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Final updated results of the NRG Oncology/NSABP protocol P-2: Study of Tamoxifen and Raloxifene(STAR) in preventing breast cancer. [abstract]. *Journal of Clinical Oncology*. 2015; 33(15S). *Presented at the 2015 ASCO Annual Meeting, May 30, Chicago, IL.*
10. **Cecchini RS**, Swain S, Costantino JP, Rastogi P (presenter), Jeong, Jong-Hyeon, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N. Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38, [abstract]. *Cancer Research*. 2013; 73(24S). *Presented at the 2013 SABCS, Dec 10-14, San Antonio, TX.*
11. Julian TB, Costantino JP, Vicini FA, White JR, **Cecchini RS**, Winter KA, Arthur DW, Kuske R, Rabinovitch R, Parda DS, Mamounas EP, Curran WJ, Wolmark N. A randomized phase III study of conventional whole breast irradiation (WBI) vs partial breast irradiation (PBI) for women with stage 0, 1, or 2 breast cancer: NSABP B-39/RTOG 0413 [abstract]. *Cancer Research*. 2011; 71(24S). *Presented at the 2011 SABCS, Dec 6-10, San Antonio, TX.*
12. Amir E, **Cecchini RS**, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1 [abstract]. *Journal of Clinical Oncology*. 2011; 29(15S). *Presented at the 2011 ASCO Meeting, Jun 3-7, Chicago, IL.*
13. Cronin WM, **Cecchini RS**, Wickerham DL, Vogel VG, Costantino JP, Wolmark N. Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) [abstract]. *Journal of Clinical Oncology*. 2008; 26(15S). *Presented at the 2008 ASCO Meeting, May 30-Jun 3, Chicago, IL.*
14. Land SR, Kopec J, **Cecchini RS**, Ganz PA, Wieand H, Colangelo L, Sharif S, Kuebler JP, Costantino J, Wolmark N. Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07 [abstract]. *Journal of Clinical Oncology*. 2006; 24(18S). *Presented at the 2006 ASCO Meeting, Jun 2-3, Atlanta, GA.*

SERVICE

1. Service to School and University

Years	Committee	Position
2018 – Present	NRG Oncology Cancer Prevention and Control Committee	Member
2014 – Present	NRG Oncology NCORP Steering Committee	Member
2014 – Present	NRG Oncology Health Disparities Committee	Member / Leader of Statistics & Metrics Working Group
2014 – Present	NRG Oncology Patient Centered Outcomes Research (PCOR) Committee	Member
2012 – 2014	NSABP Behavioral and Health Outcomes Committee	Member

2. Service to Field of Scholarship

a. Manuscript and Other Document/Publication Review

Dates	Journal Title
2019 – Present	Journal of Women's Health
2017 – Present	Journal of the National Cancer Institute
2017 - Present	JAMA Oncology
2012 – Present	Journal of Clinical Oncology

b. Study Sections, Review Panels, and Advisory Boards

Date	Position	Committee
2019 - Present	Member Advisory Board	NCI Moonshot Patient Tolerability Consortium - U01 Advancing Analysis and Interpretation of Adverse Events and PROs in Cancer Clinical Trials